Novo Nordisk, Eli Lilly rise after Viking obesity trial data

Viking Therapeutics' oral obesity drug VK2735 Phase 2 trial met its primary weight loss endpoint, but a significant 28% treatment discontinuation rate led to a more than 30% premarket stock decline for VKTX. Analysts, including Mizuho's Jared Holz, deemed the data inferior to Eli Lilly's offerings, particularly regarding the high discontinuation rate over a short trial duration. This outcome reinforced the market positions of Eli Lilly and Novo Nordisk, which saw their shares edge higher, underscoring the intense competitive pressures and the critical role of long-term tolerability in the burgeoning oral obesity market.

Analysis

Viking Therapeutics (VKTX) reported mixed results from its Phase 2 VENTURE-Oral trial for its obesity treatment, VK2735, triggering a significant market reaction. While the drug met its primary endpoint, demonstrating a notable 12.2% weight loss after 13 weeks, this efficacy was overshadowed by a high treatment discontinuation rate of 28%, compared to 18% in the placebo group. This tolerability issue prompted a more than 30% premarket plunge in VKTX shares. In contrast, shares of established competitors Eli Lilly (LLY) and Novo Nordisk (NVO) rose 1.2% and 1.4% respectively, indicating the market perceives Viking's setback as a reinforcement of their competitive moats. Analyst commentary from Mizuho underscored this view, labeling Viking's data as "inferior to LLY on almost all metrics" and highlighting that Viking's 28% discontinuation rate over 13 weeks compares unfavorably to Lilly's mid-20% rate over a much longer 72-week trial. The results emphasize that in the highly competitive oral obesity market, long-term tolerability and patient retention are as critical as efficacy for commercial viability.

Key Decisions for Investors

• Investors in Viking Therapeutics should recognize the significant clinical and commercial risk highlighted by the 28% discontinuation rate, which may impede VK2735's ability to compete with more tolerable alternatives from Eli Lilly and Novo Nordisk.
• The positive market reaction for Eli Lilly and Novo Nordisk reinforces the thesis that these incumbents possess a significant competitive advantage, suggesting that pullbacks in their stock prices could be seen as buying opportunities for those bullish on the obesity market.
• When evaluating emerging biotech competitors in the obesity space, it is crucial to scrutinize tolerability and discontinuation data with the same rigor as efficacy endpoints, as Viking's experience demonstrates this is a key hurdle to market entry.